A phase 2 clinical trial to investigate AR101 treatment with adjunctive dupilumab in patients with peanut allergies
Phase of Trial: Phase II
Latest Information Update: 08 May 2018
At a glance
- Drugs AR 101 (Primary) ; Dupilumab
- Indications Peanut hypersensitivity
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
- 08 May 2018 According to an Aimmune Therapeutics media release, Regeneron / Sanofi expects to initiate this Phase 2 trial of AR101 by year end 2018.
- 19 Oct 2017 New trial record
- 16 Oct 2017 This trial is expected to begin in 2018 according to an Aimmune Therapeutics media release.